Literature DB >> 15654150

Rate control vs. pulmonary vein isolation.

Mario D Gonzalez1.   

Abstract

Atrial fibrillation (AF) is a frequent arrhythmia encountered in clinical practice. It can be asymptomatic in some patients but incapacitating in others. Regardless of symptoms, patients at increased risk of embolism need chronic anticoagulation. In patients with AF and a rapid ventricular response that cannot be controlled with drugs, interventional procedures are required. Radiofrequency catheter ablation of the atrioventricular junction with pacemaker implantation is an effective therapeutic approach that relieves the symptoms associated with a rapid and irregular rhythm. This approach can also improve left ventricular function in patients with tachycardia-induced cardiomyopathy. Due to the irreversible nature of this approach, it is more suitable for older patients and those with advanced left ventricular dysfunction. Many patients with a structurally normal heart have symptomatic paroxysmal AF refractory to antiarrhythmic agents. This form of AF is frequently initiated by premature atrial beats arising from the pulmonary veins. A catheter ablation technique is available to electrically isolate the pulmonary veins. This procedure can eliminate AF in many patients but can result in complications, including embolic events, pulmonary veins stenosis, and cardiac perforation.

Entities:  

Mesh:

Year:  2005        PMID: 15654150     DOI: 10.1111/j.1076-7460.2005.03340.x

Source DB:  PubMed          Journal:  Am J Geriatr Cardiol        ISSN: 1076-7460


  2 in total

1.  Short-term and long-term success of electrical cardioversion in atrial fibrillation in managed care system.

Authors:  Suman S Kuppahally; Elyse Foster; Stanford Shoor; Anthony E Steimle
Journal:  Int Arch Med       Date:  2009-12-12

2.  Spontaneous, pro-arrhythmic calcium signals disrupt electrical pacing in mouse pulmonary vein sleeve cells.

Authors:  Katja Rietdorf; Martin D Bootman; Michael J Sanderson
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.